1. Home
  2. CUE vs BHM Comparison

CUE vs BHM Comparison

Compare CUE & BHM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CUE
  • BHM
  • Stock Information
  • Founded
  • CUE 2014
  • BHM 2022
  • Country
  • CUE United States
  • BHM United States
  • Employees
  • CUE N/A
  • BHM N/A
  • Industry
  • CUE Biotechnology: Pharmaceutical Preparations
  • BHM Real Estate Investment Trusts
  • Sector
  • CUE Health Care
  • BHM Real Estate
  • Exchange
  • CUE Nasdaq
  • BHM Nasdaq
  • Market Cap
  • CUE 59.5M
  • BHM 51.9M
  • IPO Year
  • CUE 2018
  • BHM N/A
  • Fundamental
  • Price
  • CUE $0.83
  • BHM $13.20
  • Analyst Decision
  • CUE Strong Buy
  • BHM Strong Buy
  • Analyst Count
  • CUE 2
  • BHM 1
  • Target Price
  • CUE $3.00
  • BHM $15.00
  • AVG Volume (30 Days)
  • CUE 118.2K
  • BHM 1.2K
  • Earning Date
  • CUE 08-12-2025
  • BHM 01-01-0001
  • Dividend Yield
  • CUE N/A
  • BHM 3.85%
  • EPS Growth
  • CUE N/A
  • BHM N/A
  • EPS
  • CUE N/A
  • BHM N/A
  • Revenue
  • CUE $8,286,000.00
  • BHM $71,496,000.00
  • Revenue This Year
  • CUE N/A
  • BHM N/A
  • Revenue Next Year
  • CUE $23.84
  • BHM N/A
  • P/E Ratio
  • CUE N/A
  • BHM N/A
  • Revenue Growth
  • CUE N/A
  • BHM 27.87
  • 52 Week Low
  • CUE $0.45
  • BHM $9.30
  • 52 Week High
  • CUE $1.99
  • BHM $16.78
  • Technical
  • Relative Strength Index (RSI)
  • CUE 53.58
  • BHM 49.08
  • Support Level
  • CUE $0.77
  • BHM $12.96
  • Resistance Level
  • CUE $0.84
  • BHM $13.18
  • Average True Range (ATR)
  • CUE 0.06
  • BHM 0.21
  • MACD
  • CUE -0.00
  • BHM -0.10
  • Stochastic Oscillator
  • CUE 71.90
  • BHM 36.59

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

About BHM Bluerock Homes Trust Inc.

Bluerock Homes Trust Inc owns and operates a portfolio of institutional residential properties including single-family homes, build-to-rent communities, and other residential communities located in attractive markets with a focus on the knowledge-economy and high-quality of life growth markets of the Sunbelt and Western United States. The company's principal objective is to generate attractive risk-adjusted returns on investments where it believes it can drive growth in funds from operations and net asset value by acquiring residential units, developing residential communities, and through value-add renovations. The Company is an externally managed REIT managed and advised by Bluerock Homes Manager, LLC.

Share on Social Networks: